Recent News

• 12.11.2025 - Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
• 12.10.2025 - Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 12.03.2025 - Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors
• 11.20.2025 - Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome
• 11.10.2025 - Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 11.06.2025 - Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
• 10.23.2025 - Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting
• 10.10.2025 - Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 10.06.2025 - Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

Recent Filings

• 12.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.01.2025 - 144 Report of proposed sale of securities
• 11.12.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.06.2025 - EX-99.1 EX-99.1
• 11.06.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.06.2025 - 8-K Current report
• 11.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.03.2025 - 144 Report of proposed sale of securities
• 10.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.01.2025 - 144 Report of proposed sale of securities